Evidence map›Paper›PMID 31110947›Full record

ArticleMolecular genetics and metabolism reports2019

Drug screening for Pelizaeus-Merzbacher disease by quantifying the total levels and membrane localization of PLP1.

Takeshi Kouga, Shiro Koizume, Shiho Aoki, Eriko Jimbo, Takanori Yamagata, Ken Inoue, Hitoshi Osaka

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular genetics and metabolism reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Takeshi KougaDepartment of Pediatrics, Jichi Medical University, Tochigi, Japan.
Shiro KoizumeKanagawa Cancer Center Research Institute, Yokohama, Japan.
Shiho AokiDepartment of Pediatrics, Jichi Medical University, Tochigi, Japan.
Eriko JimboDepartment of Pediatrics, Jichi Medical University, Tochigi, Japan.
Takanori YamagataDepartment of Pediatrics, Jichi Medical University, Tochigi, Japan.
Ken InoueDepartment of Mental Retardation and Birth Defect Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Japan.
Hitoshi OsakaDepartment of Pediatrics, Jichi Medical University, Tochigi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPelizaeus-Merzbacher disease (PMD) is caused by point mutations or copy number changes in the proteolipid protein 1 gene (

methodWe established a cell line stably expressing PLP1 RESULTS AND

conclusionPiracetam significantly increased the PLP1

Indexed as

CNS, Central nervous systemsDrug screeningEGFP, Enhanced green fluorescent proteinER-associated degradationER, Endoplasmic reticulumGene expressionIPA, Ingenuity pathways analysisIRE1 α, Inositol requiring enzyme 1 αMembrane proteinmsd, Myelin synthesis deficientOligodendrocytePLP1PLP1, Proteolipid protein 1PMD, Pelizaeus-Merzbacher diseaseUPR, Unfolded protein responseXBP1, X-box binding protein 1

Identifiers

PMID31110947
PMCPMC6510973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.